ClinicalTrials.gg
Not yet recruitingNCT06303635UFRJvac-1Updated Mar 12, 2024

Safety of UFRJvac, Trivalent COVID-19 Vaccine

An observational study in Healthy People, sponsored by Azidus Brasil. Not yet recruiting. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-12.

Sponsored by Azidus Brasil · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
156
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Phase I study to evaluate the safety and immunogenicity of the vaccine booster with the trivalent UFRJvac COVID-19 vaccine.

Read the detailed description

Phase I study to evaluate the safety and immunogenicity of the vaccine booster with the trivalent UFRJvac COVID-19 vaccine.

UFRJvac COVID-19 is a trivalent vaccine for preventing COVID-19. It is a protein subunit vaccine, being formulated with the entire recombinant spike protein ("S" protein, amino acids 1-1208) of the D614G, gamma and delta variants of SARS-CoV-2. One spike protein from each variant is expressed in HEK293 cells in trimeric form and stabilized in the prefusion conformation. In order for the adaptive immune response (humoral and cellular) to be enhanced against these proteins, the vaccine is formulated with the GLA-SE adjuvant.

The study will include 156 male or female participants aged between 18 and 65 years, with complete primary vaccination for COVID-19 and at least one booster dose, the last being carried out with the Comirnaty Bivalent BA.4/BA vaccine. 5.

UFRJvac COVID-19 will be administered once, as a booster dose, intramuscularly (0.5 mL), in doses of 5 μg or 15 μg of antigens.

Participants receive the investigational product on D0 and return for in-person medical evaluation on D2, D28, D84 and D168. Blood samples will be collected for humoral and cellular immunity tests on days D28, D84 and D168. On days D1, D3, D4, D5, D6 and D7 participants will be contacted by telephone to collect adverse events. Inclusion will be staggered, starting with 6 participants receiving PSI at a dose of 5 μg and distributed over at least 3 days. If tolerability is good, another 6 participants will receive the same dose and will also be distributed over at least 3 days. If tolerability is good, another 6 participants will receive the same dose and will be distributed over at least 3 days, totaling 18 participants with the lowest dose. If tolerability is good, another 18 participants receiving 15 μg will be included, also divided into 3 groups of 6 participants with at least 3 days of observation. If tolerability is good, an additional 120 participants will be included, 60 receiving the 5 μg dose and 60 receiving the 15 μg dose.

The main benefit of UFRJvac COVID-19 is to induce adaptive immunity against the three variants of SARS-CoV-2 (D614G, gamma and delta), and this combination of three antigens resulted, in preclinical studies, in a specific immune response also against the omicron variant. As this is a phase I study, there is still no data on adverse events related to the experimental drug. However, initially, reactions are expected at the site of product administration.

02

Conditions studied

  • Healthy People

Keywords

  • UFRJvac
03

In context

Lead sponsor

Azidus Brasil is the lead sponsor of 80 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The study will include 156 male or female participants aged between 18 and 65 years, with complete primary vaccination for COVID-19 and at least one booster dose, the last being carried out with the Comirnaty Bivalent BA.4/BA vaccine. 5.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female.
  2. Age from 18 to 65 years old, inclusive.
  3. Complete primary vaccination for COVID-19 with one of the vaccines approved by ANVISA for use in Brazil, and at least one booster, the last of which must be with Comirnaty Bivalente BA.4/BA.5 between 4 and 18 months before vaccination. inclusion.
  4. (BMI) between 19.0 and 35.0 kg/m2, inclusive.
  5. Female participant with a negative pregnancy test on the day of vaccination.
  6. Consent form voluntarily signed before any procedure.

Exclusion criteria

Exclusion Criteria:

  1. Confirmation of active SARS-CoV-2 infection in rapid antigen test screening.
  2. History of serious adverse reaction to any vaccine, medication or component of the product.
  3. History of immunodeficiency, diseases and cardiomyopathies.
  4. History of medium or major surgery within 3 months before inclusion.
  5. History of within 1 year before screening (except basal cell carcinoma of the skin or in situ carcinoma of the cervix, which have already resolved).
  6. History of uncontrolled coagulopathy or blood disorders that contraindicate intramuscular injection.
  7. History of uncontrolled epilepsy or other progressive neurological disorders such as Guillain-Barré Syndrome.
  8. Any decompensated chronic disease at the time of inclusion.
  9. Treatment with medications in the 3 months prior to the first vaccination or 6 months for chemotherapy.
  10. History of systemic (prednisone ≥ 20 mg/day or equivalent for >14 consecutive days) within 3 months prior to screening. Topical, inhaled, intranasal, and intra-articular corticosteroids are permitted regardless of dose.
  11. Use of any other vaccine less than 14 days before or planning to use up to 29 days after V0.
  12. Use of blood products in the 3 months before inclusion.
  13. Use of another investigational product within 1 year before inclusion.
  14. Pregnancy or breastfeeding at inclusion or planned during the study.
  15. Fever or any acute illness within 1 week before inclusion. Participants who do not meet this criterion may be rescheduled for a new inclusion visit.
  16. Presence of tattoos, scars, skin discoloration or any other skin disorders at the injection site that, in the opinion of the investigator, may impair the assessment of local reactogenicity.
  17. Any condition that, in the opinion of the investigator, endangers the safety or rights of the participant or makes the participant unsuitable for the study.
  18. changes in safety examinations, defined as:

    • ≤ 10.9 g/dL;
    • Leukocyte count \< 2500 cells/mm3;
    • \< 1000 cells/mm3;
    • ESR outside normal values (18 to 65 years old, male - 2 to 28 mm; 18 to 65 years old, female - 2 to 36 mm);
    • , AST and FA > 1.25 x ;
    • Total > 1.1 x ULN;
    • Creatinine > 1.1 x ULN;
    • > 5.6%;
    • Troponin 1 > 0.16 ng/mL;
    • TP and > 1.1 x ULN;
    • CPK outside normal values (male adults - 38 to 174 U/L; female adults - 26 to 140 U/L);
    • C-reactive protein > 1.0 mg/dL.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
156 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Evaluate the safety and reactogenicity of the UFRJvac COVID-19 vaccine booster

    Incidence, causality, severity and intensity of reported adverse events

    Time frame: Up to 7 days after administration.

Secondary outcomes

  1. Evaluate the safety and reactogenicity of the vaccine booster with the trivalent UFRJvac COVID-19

    Incidence, causality, severity and intensity of adverse events reported

    Time frame: 28, 84 and 168 days after administration.

  2. Evaluate the humoral immunogenicity of the vaccine booster with the trivalent UFRJvac COVID-19

    Increase in relation to the screening values of the geometric mean of the titer of neutralizing antibodies against the Wuhan and Ômicron variants of SARS-CoV-2

    Time frame: 28, 84 and 168 days after vaccination.

  3. Evaluate the humoral immunogenicity of the vaccine booster the trivalent UFRJvac COVID-19

    Percentage of participants with a 4-fold or greater increase from screening values in neutralizing antibody titers against the Wuhan and Omicron variants of SARS-CoV-2

    Time frame: 28, 84 and 168 days after vaccination.

  4. Evaluate the humoral immunogenicity of the vaccine booster with the trivalent UFRJvac

    Increase in relation to the screening values of the geometric mean of the binding antibody (IgG) titer specific for protein S

    Time frame: 28, 84 and 168 days after vaccination.

  5. Evaluate the humoral immunogenicity of the vaccine booster trivalent UFRJvac

    Percentage of participants with a 4-fold or greater increase from screening values in protein S-specific binding antibody (IgG) levels

    Time frame: 28, 84 and 168 days after vaccination.

  6. Evaluate the cellular immunogenicity of the vaccine booster with the trivalent UFRJvac COVID-19

    Increase over screening values in levels of IFN-γ, IL-2, TNF-α, IL4, IL5, and IL13 in culture supernatants from participant PBMCs

    Time frame: 28, 84 and 168 days after vaccination.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2024; primary completion for Oct 2025, 15 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2024
First posted
Mar 12, 2024
StartEst.
Jun 24, 2024
Primary completionEst.
Oct 16, 2025
CompletionEst.
Nov 25, 2025
Last update
Mar 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06303635
Lead sponsor
Azidus Brasil
Responsible party
Sponsor
First posted
Mar 12, 2024
Start date
Jun 24, 2024 (estimated)
Primary completion
Oct 16, 2025 (estimated)
Completion
Nov 25, 2025 (estimated)
Last update
Mar 12, 2024

Study contacts

Leda Castilho, PhD
Contact
leda@peq.coppe.ufrj.br
+ 55 21 3733-1985
Luciana Ferrara
Contact
luciana.ferrara@azdcro.com.br
+55 19 99523 7888
Jose Cerbino Neto, MD
principal investigator · Instituto D'Or de Ensino e Pesquisa

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion